Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors

Retrovirology

Volumn 7, Issue , 2010, Pages

  Christodoulopoulos, Ilias ^a   Droniou Bonzom, Magali E ^a   Oldenburg, Jill E ^a   Cannon, Paula M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAFILOMYCIN A1; LENTIVIRUS VECTOR; LYSINE; RETROVIRUS VECTOR; UBIQUITIN PROTEIN LIGASE E3; VIRUS ENVELOPE PROTEIN; VPU PROTEIN; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; VIRUS PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOPLASM; GENE MUTATION; GIBBON LEUKEMIA VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN FUNCTION; TRANS GOLGI NETWORK; UBIQUITINATION; VIRUS PARTICLE; VIRUS REPLICATION; WESTERN BLOTTING; CELL LINE; DRUG ANTAGONISM; GENETICS; METABOLISM;

GIBBON APE LEUKEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; CELL LINE; GENE PRODUCTS, ENV; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; LEUKEMIA VIRUS, GIBBON APE; PROTEIN INTERACTION MAPPING; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 77649123351     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-7-4     Document Type: Article

References (53)

1. Naldini L, Blömer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996, 93:11382-11388. 10.1073/pnas.93.21.11382, 38066, 8876144.
2. Kafri T, Blömer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997, 17:314-317. 10.1038/ng1197-314, 9354796.
3. Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999, 283:682-686. 10.1126/science.283.5402.682, 9924027.
4. Sinn PL, Sauter SL, McCray PB. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production. Gene Ther 2005, 12:1089-1098. 10.1038/sj.gt.3302570, 16003340.
5. Sandrin V, Russell SJ, Cosset FL. Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol 2003, 281:137-178.
6. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993, 90:8033-8037. 10.1073/pnas.90.17.8033, 47282, 8396259.
7. Emi N, Friedmann T, Yee JK. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. J Virol 1991, 65:1202-1207. 239887, 1847450.
8. O'Hara B, Johann SV, Klinger HP, Blair DG, Rubinson H, Dunn KJ, Sass P, Vitek SM, Robbins T. Characterization of a human gene conferring sensitivity by gibbon ape leukemia virus. Cell growth & differentiation 1990, 1:119-127.
9. Olah Z, Lehel C, Anderson WB, Eiden MV, Wilson CA. The cellular receptor for gibbon ape leukemia virus is a novel high affinity sodium-dependent phosphate transporter. JBC 1994, 269:25426-25431.
10. Lam JS, Reeves ME, Cowherd R, Rosenberg SA, Hwu P. Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope. Hum Gene Ther 1996, 7:1415-1422. 10.1089/hum.1996.7.12-1415, 8844200.
11. Song JJ, Kim JH, Lee H, Kim E, Kim J, Park YS, Ahn J, Yoo NC, Roh JK, Kim BS. Enhancement of gene transfer efficiency into human cancer cells by modification of retroviral vectors and addition of chemicals. Oncol Rep 2000, 7:119-124.
12. Stitz J, Buchholz CJ, Engelstädter M, Uckert W, Bloemer U, Schmitt I, Cichutek K. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 2000, 273:16-20. 10.1006/viro.2000.0394, 10891403.
13. Christodoulopoulos I, Cannon PM. Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentiviral vectors. J Virol 2001, 75:4129-4138. 10.1128/JVI.75.9.4129-4138.2001, 114158, 11287562.
14. Merten CA, Stitz J, Braun G, Poeschla EM, Cichutek K, Buchholz CJ. Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles. J Virol 2005, 79:834-840. 10.1128/JVI.79.2.834-840.2005, 538528, 15613311.
15. Schubert U, Strebel K. Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol 1994, 68:2260-2271. 236702, 8139011.
16. Paul M, Jabbar MA. Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpu-mediated ER degradation of CD4. Virology 1997, 232:207-216. 10.1006/viro.1997.8541, 9185604.
17. Fujita K, Satoshi O, Silver J. Rapid degradation of CD4 in cells expressing human immunodeficiency virus type 1 Env and Vpu is blocked by proteasome inhibitors. J Gen Virol 1997, 78:619-625.
18. Margottin F, Bour SP, Durand H, Selig L, Benichou S, Richard V, Thomas D, Strebel K, Benarous R. A novel human WD protein, h-beta TrCP, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998, 1:1565-1574.
19. Schubert U, Anton LC, Bacik I, Cox JH, Bour S, Bennink JR, Orlowski M, Strebel K, Yewdell JW. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol 1998, 72:2280-2288. 109526, 9499087.
20. Evrard-Todeschi N, Gharbi-Benarous J, Bertho G, Coadou G, Megy S, Benarous S, Girault JP. NMR studies for identifying phosphopeptide ligands of the HIV-1 protein Vpu binding to the F-box protein beta-TrCP. Peptides 2006, 27:194-210. 10.1016/j.peptides.2005.07.018, 16165251.
21. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Früh K, Moses AV. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J Virol 2009, 83:7931-7947. 10.1128/JVI.00242-09, 19515779.
22. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. Plos Pathog 2009, 5:e1000450. 10.1371/journal.ppat.1000450, 2679223, 19478868.
23. Goffinet C, Allespach I, Homann S, Tervo HM, Habermann A, Rupp D, Oberbremer L, Kern C, Tibroni N, Welsch S, Krijnse-Locker J, Banting G, Kräusslich HG, Fackler OT, Keppler OT. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 2009, 5:285-297. 10.1016/j.chom.2009.01.009, 19286137.
24. Schlesinger MJ, Schlesinger S. Domains of virus glycoproteins. Adv Virus Res 1987, 33:1-44. full_text, 3296693.
25. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotech 1997, 15:871-875.
26. Ragheb JA, Anderson WF. pH-independent murine leukemia virus ecotropic envelope-mediated cell fusion: implications for the role of the R peptide and p12E TM in viral entry. J Virol 1994, 68:3220-3231. 236813, 8151784.
27. Rein A, Mirro J, Haynes JG, Ernst SM, Nagashima K. Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein. J Virol 1994, 68:1773-1781. 236638, 8107239.
28. Kiernan RE, Freed EO. Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations. J Virol 1998, 72:9621-9627. 110471, 9811695.
29. Willey RL, Maldarelli F, Martin MA, Strebel K. Human immunodeficiency virus type I Vpu protein induces rapid degradation of CD4. J Virol 1992, 66:7193-7200. 240416, 1433512.
30. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430. 10.1038/nature06553, 18200009.
31. Bedgood R, Stallcup MR. A novel intermediate in processing of murine leukemia virus envelope glycoproteins. Proteolytic cleavage in the late Golgi region. JBC 1992, 267:7060-7065.
32. Wu BW, Cannon PM, Gordon EM, Hall FL, Anderson WF. Characterization of the proline-rich region of murine leukemia virus envelope protein. J Virol 1998, 72:5383-5391. 110165, 9620992.
33. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. Ann Rev Biochem 1985, 54:631-664. 10.1146/annurev.bi.54.070185.003215, 3896128.
34. Roth J. Subcellular organization of glycosylation in mammalian cells. Biochim Biophys Acta 1987, 906:405-436.
35. Reignier T, Oldenburg J, Noble B, Lamb E, Romanowski V, Buchmeier MJ, Cannon PM. Receptor use by pathogenic arenaviruses. Virology 2006, 353:111-120. 10.1016/j.virol.2006.05.018, 16797051.
36. Desmaris N, Bosch A, Salaün C, Petit C, Prévost MC, Tordo N, Perrin P, Schwartz O, de Rocquigny H, Heard JM. Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. Mol Ther 2001, 4:149-156. 10.1006/mthe.2001.0431, 11482987.
37. Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Virol 2000, 74:4933-4937. 10.1128/JVI.74.10.4933-4937.2000, 112022, 10775638.
38. Sandrin V, Boson B, Salmon P, Gay W, Nègre D, Le Grand R, Trono D, Cosset FL. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002, 100:823-832. 10.1182/blood-2001-11-0042, 12130492.
39. Nomaguchi M, Fujita M, Adachi A. Role of HIV-1 Vpu protein for virus spread and pathogenesis. Microbes Infect 2008, 10:960-967. 10.1016/j.micinf.2008.07.006, 18672082.
40. Bour S, Schubert U, Strebel K. The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol 1995, 69:1510-1520. 188742, 7853484.
41. Willey RL, Buckler-White A, Strebel K. Sequences present in the cytoplasmic domain of CD4 are necessary and sufficient to confer sensitivity to the human immunodeficiency virus type 1 Vpu protein. J Virol 1994, 68:1207-1212. 236563, 8289353.
42. Chen MY, Maldarelli F, Karczewski MK, Willey RL, Strebel K. Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: the cytoplasmic domain of CD4 contributes to Vpu sensitivity. J Virol 1993, 67:3877-3884. 237753, 8510209.
43. Lenburg ME, Landau NR. Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4. J Virol 1993, 67:7238-7245. 238186, 8230446.
44. Sandrin V, Muriaux D, Darlix JL, Cosset FL. 2004. Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses. J Virol 2004, 78:7153-7164. 10.1128/JVI.78.13.7153-7164.2004, 421692, 15194792.
45. Sandrin V, Cosset FL. Intracellular versus cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag, and the expression of the Nef protein. JBC 2006, 281:528-542.
46. Willey RL, Maldarelli F, Martin MA, Strebel K. Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol 1992, 66:226-234. 238279, 1727486.
47. Aiken C, Konner J, Landau NR, Lenburg ME, Trono D. Nef induces CD4 endocytosis: requirement of a critical dileucine motif in the membrane proximal CD4 cytoplasmic domain. Cell 1994, 76:853-864. 10.1016/0092-8674(94)90360-3, 8124721.
48. Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface CD4 by Nef. Nature 1991, 350:508-511. 10.1038/350508a0, 2014052.
49. Kirkham LA, Bateman AR, Melcher AA, Vile RG, Fielding AK. Lack of specificity of cell-surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein. J Gene Med 2002, 4:592-600. 10.1002/jgm.306, 12439851.
50. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995, 23:628-633. 10.1093/nar/23.4.628, 306730, 7899083.
51. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267. 10.1126/science.272.5259.263, 8602510.
52. Pinter A, Honnen WJ, Tung JS, O'Donnell PV, Hammerling U. Structural domains of endogenous murine leukemia virus gp70s containing specific antigenic determinants defined by monoclonal antibodies. Virology 1982, 116:499-516. 10.1016/0042-6822(82)90143-X, 6175079.
53. Maldarelli F, Chen M-Y, Willey RL, Strebel K. Human immunodeficiency virus type 1 Vpu protein is an oligomeric type 1 integral membrane protein. J Virol 1993, 67:5056-5061. 237897, 8331740.